10x Genomics is a life sciences tools company that sells integrated workflows for high-resolution analysis of biological samples, combining instruments, proprietary consumables, and bundled software. Its commercial portfolio centers on Single Cell and Spatial biology solutions used to study complex tissues and cellular systems in areas such as oncology, immunology, and neuroscience. The company’s model is built around an installed base of instruments (e.g., Chromium and Xenium) that drives recurring pull-through demand for single-use consumables designed to work with those platforms. It sells globally to research-focused institutions and also earns smaller streams from service contracts and licensing/royalties tied to its intellectual property.
−3,9 %
69,1 %
−6,8 %
+5,2 %
4.46
4.09
| % | |
|---|---|
| Single Cell solutions | 60% Chromium instruments and single cell consumables for partitioning and profiling cells at scale. |
| Spatial solutions | 33% Visium and Xenium platforms plus consumables for spatial and in situ analysis in tissue context. |
| Service agreements | 4% Post-warranty service contracts and extended coverage for installed instruments. |
| License and royalty revenue | 3% Up-front IP license fees, running royalties, and allocated amounts from patent litigation settlements. |
10x Genomics sells primarily to research organizations that need standardized, high-throughput workflows for single...
Purchase instruments for lab and core-facility workflows and drive recurring consumable usage for publications and grants.
Buy platforms for large-scale research programs and shared facilities, often with structured procurement cycles.
Adopt single cell and spatial tools for translational research, target discovery, and biomarker development; expected to grow in mix.
Use the platforms to develop and validate novel biology insights and support pipeline decisions with high-resolution data.
10x Genomics sells in over 50 countries and supports customers through a mix of direct sales and third-party...
The company’s strategy emphasizes continued investment in new solutions and new versions of existing products to expand...
Customer demand is shaped by rapid technology change and new assay modalities; product relevance drives adoption and utilization.
The installed-base model depends on recurring consumable reactions per instrument and broader adoption within labs and core facilities.
Adding complementary IP/technology can shorten development cycles and expand the product roadmap beyond internal R&D.
Demand risk is elevated because customers operate in research environments with rapid technology shifts; a delayed or...
Tariffs, export/import restrictions and changing U.S.-China policies can reduce demand, raise costs, or limit market access.
Long lead times require assumptions about analytes, methods, and use cases; launches may miss performance/price expectations or be displaced.
A significant breach or outage could affect critical systems, data integrity, and business continuity; reliance on key service providers adds exposure.
The business depends on protecting proprietary microfluidics and assay IP; disputes can be costly and outcomes uncertain.
WGS · Services-Health Services
BNGO · Laboratory Analytical Instruments
BMRA · In Vitro & In Vivo Diagnostic Substances
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
HBIO · Laboratory Analytical Instruments
Harvard Bioscience designs, manufactures, and sells life-science research tools used in drug discovery, translational medicine, and preclinical testing.
IBO · Pharmaceutical Preparations
: 11/08/2026